Wird geladen...
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
BACKGROUND: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study was to determine the effect of tofacitinib on patient-reported ou...
Gespeichert in:
| Veröffentlicht in: | BMC Gastroenterol |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4323227/ https://ncbi.nlm.nih.gov/pubmed/25651782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0239-9 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|